Neuronetics Reports Second Quarter 2026 Financial and Operating Results

Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Neuronetics Reports Second Quarter 2026 Financial and Operating Results MALVERN, PA., August 11, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar ® TMS technology with direc

Event · Earnings
Also in this documentGuidance · lower · $160M–$164M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Aug 11, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 12:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$STIM
Bullish
medium confidence
Mentioned
$STIM
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$STIMBullishMed
01

Why it matters

The filing updates investors on profitability trajectory (adjusted EBITDA and operating loss improvement), cash position deterioration, and full-year guidance changes, which can drive re-rating of near-term execution risk.

02

Market read

Traders can reassess STIM’s execution against guidance using the disclosed Q2 metrics (revenue, gross margin, adjusted EBITDA, net loss) and the updated FY 2026 ranges, including cash flow expectations.

03

What to watch

Operating expense guidance excludes stock-based compensation, so investors should focus on GAAP operating loss trajectory and the pace of cash burn versus the stated cash flow range.

Relevance 7/10Novelty 8/10Timing: pre-market today (8-K filed Aug 11, 2026)
AlphAI · Earnings readSTIM · Second Quarter 2026 · ended June 30, 2026

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

✓Solid quarter

Total revenue increased 9.1%, Greenbrook revenue increased 16.8%, gross margin expanded to 51.1%, operating expenses declined 12%, and Adjusted EBITDA improved to $0.3 million from a loss of $5.6 million. NeuroStar revenue declined 2.7%, the company remained loss-making, and total cash was lower than at December 31, 2025.

Revenue
$41.6M
9.1% y/y
NeuroStar revenue
$14.7M
(2.7 )% y/y
Gross margin · GAAP
51.1%
EPS · GAAP
$0.05
full year 2026 outlook
$160 million and $164 million
GM 48% and 50%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenueGAAP$41.6M–9.1%
Gross marginGAAP51.1%––
Operating expensesGAAP$22.7M–12%
Loss from operationsGAAP$1.5M–decrease of $6.6 million
Adjusted EBITDAnon-GAAP$300K–increase of $5.9 million
Net lossGAAP$3.4M––
Net loss per shareGAAP$0.05 per share––
Weighted average common shares outstandingGAAP73,129,107––
Net cash used in operations and investingother$1.4M–reduction of $2.3 million
Total cashother$25M––
Cash and cash equivalentsother$19.2M––
Restricted cashother$5.8M––

Segments

SegmentRevenueq/qy/y
NeuroStar revenueThe company said it is broadening how customers can access its technology through expanded NeuroStar go-to-market models.$14.68M–(2.7 )%
Greenbrook revenueThe increase reflected continued growth of the Greenbrook business.$26.89M–16.8 %

full year 2026 outlook

  • Revenue$160 million and $164 million
  • Gross margin48% and 50%
  • Operating expenses$95 million to $100 million
  • NoteOperating expenses, less SBC: $91 million to $96 million
  • NoteEstimated stock-based compensation: $4 million
  • NoteCash flow from operations and investing in the range of negative $10.5 million to negative $14.5 million

What drove it

  • Total revenue growth was primarily driven by higher Greenbrook revenue.
  • Gross-margin expansion was driven by the positive impact of the new go-to-market strategy and improved revenue cycle management within the Greenbrook clinics.
  • Operating-expense reduction was primarily attributable to lower general and administrative expenses and lower sales and marketing expenses.
  • The company strengthened leadership with the appointment of Nir Naor as Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer; the promotion of Cory Anderson to Executive Vice President and General Manager of Greenbrook; and the appointment of Rob Greene as Senior Vice President, Sales.

Concerns

  • NeuroStar revenue declined (2.7 )% year over year.
  • The company reported a net loss of $3.4 million and a loss from operations of $1.5 million.
  • Total cash was $25 million as of June 30, 2026, compared to total cash of $34.1 million as of December 31, 2025.
  • Full-year 2026 guidance calls for cash flow from operations and investing in the range of negative $10.5 million to negative $14.5 million.

What to watch

  • Execution of expanded NeuroStar go-to-market models and whether NeuroStar revenue returns to growth.
  • Continued Greenbrook revenue growth and revenue-cycle-management improvements within the clinics.
  • Sustainability of gross margin in the guided range of 48% and 50%.
  • Progress toward the company's goal of sustained profitability and positive net cash flow from operations and investing.
  • Operating-expense delivery against the $95 million to $100 million full-year guidance range.

Balance sheet and cash flow

  • As of June 30, 2026, the Company held $25 million in total cash, consisting of cash and cash equivalents of $19.2 million and $5.8 million of restricted cash, compared to total cash of $34.1 million as of December 31, 2025.
  • Net cash used in operations and investing of $1.4 million, a reduction of $2.3 million compared to $3.8 million in the second quarter of 2025.

Analysis

Neuronetics delivered year-over-year revenue growth in the second quarter, with total revenue of $41.6 million, up 9.1% from $38.1 million. The growth was driven by Greenbrook revenue of $26.9 million, up 16.8%, while NeuroStar revenue was $14.7 million and declined 2.7%. The segment mix makes Greenbrook the documented source of growth, while the NeuroStar decline remains the principal demand issue identified in the reported segment results.

Profitability improved materially. Gross margin increased to 51.1% from 46.6%, which the company attributed to its new go-to-market strategy and improved revenue cycle management in Greenbrook clinics. Operating expenses declined to $22.7 million from $25.8 million, primarily due to lower general and administrative expense and lower sales and marketing expense. Those changes reduced loss from operations to $1.5 million from a loss of $8.1 million and brought Adjusted EBITDA to $0.3 million from a loss of $5.6 million.

The company remained unprofitable on a GAAP basis, reporting a net loss of $3.4 million, or $0.05 per share, compared with a net loss of $10.1 million, or $0.15 per share. Net cash used in operations and investing was $1.4 million, compared to $3.8 million in the second quarter of 2025. Total cash was $25 million as of June 30, 2026, compared with $34.1 million as of December 31, 2025, and consisted of $19.2 million in cash and cash equivalents and $5.8 million in restricted cash.

For full-year 2026, the company expects total revenue between $160 million and $164 million, gross margin between 48% and 50%, and operating expenses between $95 million to $100 million. It also expects operating expenses less stock-based compensation of $91 million to $96 million, with estimated stock-based compensation of $4 million. The company expects cash flow from operations and investing in the range of negative $10.5 million to negative $14.5 million. The release contains no first-quarter 2026 figures, so it does not support a documented sequential comparison.

The key operating focus is whether the new NeuroStar access and go-to-market models can reverse the reported revenue decline while Greenbrook continues to grow. Investors should also focus on the durability of the gross-margin improvement, execution against the reduced operating-expense outlook, and cash use against the full-year cash-flow guidance. Leadership changes place finance, Greenbrook clinic operations, and NeuroStar sales under newly appointed or promoted executives during this execution period.

Management, verbatim

This was a quarter of real operational progress, and meaningful steps toward our goal of sustained profitability and positive net cash flow from operations and investing.

Dan Reuvers, President and Chief Executive Officer of Neuronetics

For some time, NeuroStar has not competed to its full potential, and we are changing that by broadening how customers can access our technology while we continue to drive operational gains across the Greenbrook clinics.

Dan Reuvers, President and Chief Executive Officer of Neuronetics

Not in the filing

stated, not guessed
  • Prior-quarter revenue, segment revenue, gross margin, operating expenses, operating income or loss, net income or loss, EPS, Adjusted EBITDA, and cash-flow comparisons were not reported.
  • Gross profit was not reported.
  • GAAP operating income was not reported; the company reported loss from operations.
  • Non-GAAP net income or loss and non-GAAP EPS were not reported.
  • Operating cash flow and investing cash flow as separate line items were not reported.
  • Free cash flow was not reported.
  • Debt was not reported.
  • Capital returns, including share repurchases and dividends, were not reported.
  • Tax rate was not reported.
  • A prior quarterly outlook document was not provided, so no reported actual-versus-prior-guidance comparison is included.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Neuronetics operates NeuroStar TMS technology and the Greenbrook interventional psychiatry clinic network, and this 8-K reports Q2 2026 results plus FY 2026 outlook.

Company-level read

Ticker impact

$STIMBullishMedium confidence
Context

Neuronetics reported Q2 2026 results and updated FY 2026 guidance, including revenue $160M-$164M and cash flow from operations and investing of negative $10.5M to negative $14.5M.

Expected impact

Likely positive near-term bias if investors view the EBITDA improvement and guidance tightening as credible progress toward profitability, but cash balance decline may cap upside.

Evidence & confidence

The filing provides multiple decision-relevant datapoints: Q2 revenue growth (+9.1%), adjusted EBITDA improvement to $0.3M, net loss narrowing, and explicit FY 2026 guidance ranges plus a cash flow outlook.

Market effects

Signals improving unit economics and go-to-market execution for interventional mental health providers combining device sales with care-delivery networks.

No specific regional spillover beyond US small-cap healthcare sentiment.

Limited, as the disclosure is company-specific and not tied to global regulatory or supply-chain events.

Counterpoint

Despite improved adjusted EBITDA, the company still reported a net loss and reduced cash from $34.1M to $25.0M, so the market may discount the sustainability of progress.

Key entities

  • Neuronetics, Inc.

    Reported Q2 2026 financial and operating results and provided updated FY 2026 guidance in an SEC 8-K.

  • Greenbrook

    Clinic network segment; revenue grew to $26.9M in Q2 2026 and drove overall revenue growth.

  • Nir Naor

    Appointed Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer.

  • Cory Anderson

    Promoted to Executive Vice President and General Manager of Greenbrook clinics.

  • Rob Greene

    Appointed Senior Vice President, Sales.

Every STIM earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$STIMHigh

Why is Neuronetics stock tumbling today?

Neuronetics Inc's stock fell 11.4% in pre-market trading after pricing a $30M share offering at a discount. The company aims to use proceeds to address going concern risks and meet a $15M loan prepayment deadline by November 30, 2026. Despite Q3 revenue growth, these factors drove the decline, with no broader market impact.

$STIMHigh

Neuronetics stock tumbles 10% on stock offering launch

Neuronetics Inc (STIM) shares dropped 10% in after-hours trading after announcing a public stock offering and a credit agreement amendment. The company aims to sell shares with a 30-day option for underwriters to buy 15% more. The amendment reduces revenue covenants if certain conditions are met by November 30, 2026, addressing going concern risks. William Blair, BTIG, and Canaccord Genuity are managing the offering.

$STIMHigh

Neuronetics Inc (STIM) (Q3 2026) Earnings Call Highlights: Revenue Jumps

Neuronetics Inc (STIM) reported Q3 2026 revenue of $42M, up 12.5% YoY, driven by Greenbrook's 20.1% growth. Gross margin expanded to 52.2%, and operating expenses decreased 12.6%, leading to positive adjusted EBITDA of $1.9M. NeuroStar revenue grew only 1.8% YoY, with session revenue declining. Cash balance decreased to $27.9M. Management expects full-year 2026 cash flow to be negative $10M to $12M.

$STIMMed

Neuronetics Q3 Earnings Call Highlights

Neuronetics reported Q3 revenue growth driven by record system sales, with capital and lease units making up over half of sales. The company expects lower treatment-session revenue as it shifts focus to larger customers. Neuronetics anticipates higher growth in 2027 and beyond. It also submitted a 510(k) application for an accelerated TMS protocol and cited a study showing treatment gaps do not reduce effectiveness.